|
Office Locations:
|
c/o MDA National Office
1016 W Jackson Blvd #1073
Chicago, IL 60607
Phone: 800-572-1717
| | |
|
|
|
Life Sciences & Healthcare
|
|
|
MDA Venture Philanthropy (MVP) is the Muscular Dystrophy Association's drug development program, which operates within MDA's Translational Research program. MVP is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. MVP seeks to utilize scientific and business best practices to drive the market for therapeutic development in the following target areas: Amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease); Duchenne muscular dystrophy; Spinal muscular atrophy; and other neuromuscular diseases (Friedreich's ataxia, myotonic muscular dystrophy, limb-girdle muscular dystrophy, etc.). MVP evaluates and makes targeted investments in for-profit and not-for-profit companies and academics developing therapeutics for neuromuscular diseases. MDA Venture Philanthropy (MVP) does not provide traditional grants, but rather makes targeted investments in drug development for neuromuscular disease. Projects will be milestone-driven, contract-mediated and a return on investment will be negotiated. MVP utilizes a professional diligence process and is committed to a 16-week turnaround on investment decisions.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
COMPANY STAGE | REVENUE |
Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
Private Equity | |
Lower Middle Market | $10M-$249M |
Middle Market | $250M-$499M |
Upper Middle Market | $500M-$1B |
Large Cap | >$1B |
|
|
|
|